MILAN: Indian pharmaceutical companies at CPHI Milan, Italy’s flagship pharma and chemicals expo, are looking to expand their businesses beyond traditional generic exports, as they explore collaborations, licensing deals, contract manufacturing, and higher-value products. The shift comes as geopolitical tensions, tariffs, and supply-chain disruptions push drugmakers to diversify markets and build a stronger foothold in global pharmaceutical supply chains.
In today’s turbulent economic environment, the opportunity for Indian drugmakers is no longer limited to manufacturing medicines at lower costs for overseas markets and selling them overseas, companies at the expo told The Economic Times Digital . They said the focus is now shifting towards becoming strategic partners to global drugmakers through R&D, CDMO (contract development and manufacturing), licensing, co-development and access to regulated markets.
